Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pediatric Endocrinology

Understanding Your Child's IGHD Diagnosis

At a Glance

Non-acquired isolated growth hormone deficiency (IGHD) is a rare genetic condition where a child's pituitary gland does not produce enough growth hormone. With early diagnosis and daily treatment using synthetic growth hormone, children can achieve normal adult height and a normal life expectancy.

Receiving a diagnosis of Isolated Growth Hormone Deficiency (IGHD) can feel overwhelming, leaving you with many questions about your child’s future. It is important to know that you are not alone, and this condition is not a result of anything you did or did not do during pregnancy or early childhood [1]. For most children with this diagnosis, the path forward is well-traveled by specialists, and effective treatments are available to help your child reach their full growth potential [2][3].

Defining Isolated Growth Hormone Deficiency

Isolated Growth Hormone Deficiency (IGHD) is a condition where the pituitary gland (a pea-sized gland at the base of the brain) does not produce enough growth hormone (GH) [4]. “Isolated” means that while the body is low on growth hormone, all other hormones produced by the pituitary—such as those that control the thyroid or adrenal glands—are typically functioning normally at the time of diagnosis [4][5].

In the “non-acquired” or congenital form, the condition is present from birth. It is often caused by instructions in the child’s DNA (genetic mutations) that affect how growth hormone is made or released [5][6].

Grounding Facts for Parents

When a child is diagnosed with a rare condition, it helps to focus on the “stabilizing facts” that medical research provides:

  • It is Rare but Well-Understood: Non-acquired growth hormone deficiency affects approximately 1 in 4,000 to 1 in 10,000 children [7]. Because it has been studied for decades, doctors have very clear protocols for treatment and monitoring [8].
  • Highly Effective Treatment: The standard treatment, recombinant human growth hormone (rhGH), is a synthetic version of the hormone the body is missing [2]. It has a long track record of helping children increase their growth velocity and reach a final adult height within the normal range [9][10].
  • Normal Life Expectancy: Research indicates that children treated for IGHD do not have a shorter life expectancy compared to the general population [11].
  • Comprehensive Health Benefits: Beyond height, growth hormone replacement helps maintain healthy bone mineral density (bone strength), normal metabolic health, and a healthy balance of muscle and fat as the child grows [12][13].

Why This Happened: The Role of Genetics

In non-acquired IGHD, the cause is usually a change in a specific gene, such as GH1 or GHRHR [5][14]. These genes act like a blueprint for growth; if the blueprint has a tiny error, the “factory” (the pituitary gland) cannot build the hormone correctly [4].

Doctors often categorize genetic IGHD into four types based on how the gene was passed down:

  1. Type IA: The most severe form, where the body produces virtually no growth hormone [6].
  2. Type IB: The body produces very low levels of growth hormone [5].
  3. Type II: An “autosomal dominant” form, meaning it can be passed from just one parent who might also be short in stature [4].
  4. Type III: A rare form linked to the X-chromosome [6].

Even when a genetic cause is suspected, sometimes current tests cannot find the specific mutation. This is called idiopathic IGHD, but it is treated the same way and carries the same positive outlook with therapy [15].

Looking Ahead

While IGHD is “isolated” at diagnosis, your child’s care team will continue to monitor them over the years. In some cases, children with congenital IGHD can develop other hormone deficiencies later in life, a condition known as Multiple Pituitary Hormone Deficiency (MPHD) [16][17]. Regular follow-ups with a pediatric endocrinologist (a doctor specializing in children’s hormones) ensure that any changes are caught early and managed effectively [18][19].

Early diagnosis and starting treatment early are the most important steps in helping your child grow and thrive [20][21].

Common questions in this guide

What causes isolated growth hormone deficiency in children?
In the non-acquired or congenital form, IGHD is usually caused by genetic mutations present from birth. These genetic changes affect how the pituitary gland produces or releases growth hormone, even though other pituitary hormones function normally.
How is isolated growth hormone deficiency treated?
The standard treatment is recombinant human growth hormone (rhGH), which is a synthetic version of the missing hormone. This therapy is highly effective and helps children increase their growth velocity to reach a normal adult height.
Will my child with IGHD have a normal life expectancy?
Yes, children treated for isolated growth hormone deficiency have a normal life expectancy. Alongside promoting growth, treatment provides comprehensive health benefits, including healthy bone density and normal metabolic function.
Can isolated growth hormone deficiency lead to other problems later?
While IGHD only affects growth hormone at the time of diagnosis, some children may develop other pituitary hormone deficiencies over time. Regular monitoring by a pediatric endocrinologist is crucial to catch and manage any new hormone deficiencies early.
Why might genetic testing be recommended for my child's IGHD?
Genetic testing helps identify specific gene mutations, such as changes in the GH1 or GHRHR genes, that act as the blueprint for growth hormone. Identifying the exact mutation can help doctors categorize the specific type of deficiency and tailor your child's long-term care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my child's IGHD likely caused by a genetic mutation, and is genetic testing recommended for our family?
  2. 2.Did the pituitary MRI show any structural differences, such as Pituitary Stalk Interruption Syndrome (PSIS)?
  3. 3.What were the peak growth hormone levels during the stimulation tests, and what do those numbers tell us about the severity?
  4. 4.How will we monitor for the possibility of other hormone deficiencies developing over time?
  5. 5.Based on my child's current height and age, what are the realistic goals for their growth with treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Children's psychosocial functioning and parents' quality of life in paediatric short stature: The mediating role of caregiving stress.

    Silva N, Bullinger M, Sommer R, et al.

    Clinical psychology & psychotherapy 2018; (25(1)):e107-e118 doi:10.1002/cpp.2146.

    PMID: 28960605
  2. 2

    Recombinant growth hormone improves growth and adult height: a comparison between treated and untreated patients with idiopathic growth hormone deficiency.

    Zhao Q, Li R, Shao Q, et al.

    Translational pediatrics 2025; (14(3)):442-451 doi:10.21037/tp-2024-576.

    PMID: 40225070
  3. 3

    Approach to the Patient: Case Studies in Pediatric Growth Hormone Deficiency and Their Management.

    Henry RK, Miller BS

    The Journal of clinical endocrinology and metabolism 2023; (108(11)):3009-3021 doi:10.1210/clinem/dgad305.

    PMID: 37246615
  4. 4

    Isolated growth hormone deficiency due to the R183H mutation in GH1: Clinical analysis of a four-generation family.

    Cabrera-Salcedo C, Shah AS, Andrew M, et al.

    Clinical endocrinology 2017; (87(6)):874-876 doi:10.1111/cen.13400.

    PMID: 28626954
  5. 5

    Contribution of functionally assessed GHRHR mutations to idiopathic isolated growth hormone deficiency in patients without GH1 mutations.

    Cohen E, Belkacem S, Fedala S, et al.

    Human mutation 2019; (40(11)):2033-2043 doi:10.1002/humu.23847.

    PMID: 31231873
  6. 6

    Mutations in GH1 gene and isolated growth hormone deficiency (IGHD): A familial case of IGHD type I and systematic review.

    Li Q, Xu Z, Zhang M, et al.

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2021; (60-61()):101423 doi:10.1016/j.ghir.2021.101423.

    PMID: 34375817
  7. 7

    Evaluation of Growth Hormone Deficiency in Children with Cystic Fibrosis.

    Reisi M, Sharif Ahmadian N, Hashemipour M, et al.

    Advanced biomedical research 2022; (11()):62 doi:10.4103/abr.abr_285_20.

    PMID: 36124019
  8. 8

    Questioning the Value of Brain Magnetic Resonance Imaging in the Evaluation of Children with Isolated Growth Hormone Deficiency.

    Oren A, Singer D, Rachmiel M, et al.

    Hormone research in paediatrics 2020; (93(4)):245-250 doi:10.1159/000509366.

    PMID: 32836222
  9. 9

    Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency.

    Riaz M, Ibrahim MN, Rai VR, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024; (34(8)):932-935 doi:10.29271/jcpsp.2024.08.932.

    PMID: 39113512
  10. 10

    [Somatropin and final height in Mexican paediatric population with growth hormone deficiency].

    Rivera-Hernández A, Sánchez-García F, Zurita-Cruz J, Balcázar-Hernández L

    Andes pediatrica : revista Chilena de pediatria 2022; (93(4)):496-503 doi:10.32641/andespediatr.v93i4.3763.

    PMID: 37906847
  11. 11

    Mortality Is Not Increased in Recombinant Human Growth Hormone-treated Patients When Adjusting for Birth Characteristics.

    Albertsson-Wikland K, Mårtensson A, Sävendahl L, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(5)):2149-59 doi:10.1210/jc.2015-3951.

    PMID: 26918292
  12. 12

    Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy.

    Yuan Y, Zhou B, Liu S, et al.

    Endocrine 2021; (71(1)):35-46 doi:10.1007/s12020-020-02435-w.

    PMID: 32740695
  13. 13

    Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy.

    Rossini A, Lanzi R, Galeone C, et al.

    Endocrine 2021; (74(3)):666-675 doi:10.1007/s12020-021-02835-6.

    PMID: 34331234
  14. 14

    Pathogenic and likely pathogenic genetic alterations and polymorphisms in growth hormone gene (GH1) and growth hormone releasing hormone receptor gene (GHRHR) in a cohort of isolated growth hormone deficient (IGHD) children in Sri Lanka.

    Sundralingam T, Tennekoon KH, de Silva S, et al.

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2017; (36()):22-29 doi:10.1016/j.ghir.2017.08.006.

    PMID: 28910730
  15. 15

    Genetic causes of isolated and combined pituitary hormone deficiency.

    Giordano M

    Best practice & research. Clinical endocrinology & metabolism 2016; (30(6)):679-691 doi:10.1016/j.beem.2016.09.005.

    PMID: 27974184
  16. 16

    Progression from isolated growth hormone deficiency to combined pituitary hormone deficiency.

    Cerbone M, Dattani MT

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2017; (37()):19-25 doi:10.1016/j.ghir.2017.10.005.

    PMID: 29107171
  17. 17

    Clinical Presentation of Congenital Hypopituitarism: Lessons From a Large Academic Centre.

    Ladd JM, Pyle-Eilola AL, Mamilly L, et al.

    Clinical endocrinology 2025; (102(6)):649-655 doi:10.1111/cen.15213.

    PMID: 39905798
  18. 18

    Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: Frequencies, phenotypes and growth outcomes.

    Blum WF, Klammt J, Amselem S, et al.

    EBioMedicine 2018; (36()):390-400 doi:10.1016/j.ebiom.2018.09.026.

    PMID: 30266296
  19. 19

    Congenital hypopituitarism: how to select the patients for genetic analyses.

    Crisafulli G, Aversa T, Zirilli G, et al.

    Italian journal of pediatrics 2018; (44(1)):47 doi:10.1186/s13052-018-0484-y.

    PMID: 29625578
  20. 20

    Growth, development, puberty and adult height before and during treatment in children with congenital isolated growth hormone deficiency.

    Smuel K, Kauli R, Lilos P, Laron Z

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2015; (25(4)):182-8.

    PMID: 26077773
  21. 21

    Health and Lifestyle of Adult Patients with Congenital Isolated Growth Hormone Deficiency Treated in Childhood.

    Ben-Nun Yaari E, Kauli R, Lilos P, Laron Z

    The Israel Medical Association journal : IMAJ 2019; (21(3)):189-193.

    PMID: 30905105

This page provides educational information about pediatric Isolated Growth Hormone Deficiency (IGHD) and is not a substitute for professional medical advice. Always consult your child's pediatric endocrinologist regarding diagnosis and treatment plans.

Get notified when new evidence is published on Non-acquired isolated growth hormone deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.